John Kang, The Asian Lawyer

September 05, 2018 | International Edition

David Hall-Jones has retired from the firm, which has seen a spate of departures from its Asian offices. The firm has not named a replacement.

By John Kang

3 minute read

September 05, 2018 | International Edition

• Paul Hastings, Kirkland act on $700 million spin-off of Chinese conglomerate Fosun International's tourism and hotels unit. • Wilson Sonsini, Davis Polk on China Biologic's $590 million share sale. • Norton Rose, Ashurst on Korean steel giant's $280 million acquisition of lithium mining rights in Argentina.

By John Kang | Anna Zhang

3 minute read

September 04, 2018 | International Edition

Singapore-based corporate partner Karun Cariappa and Hong Kong-based investment management partner Helen Fok have joined Morgan Lewis from the U.K.-based firm.

By John Kang

2 minute read

September 03, 2018 | International Edition

The legacy Berwin Leighton Paisner base in Beijing and Bryan Cave office in Shanghai are expected to officially become part of BCLP in four-to-six weeks.

By John Kang

2 minute read

September 02, 2018 | International Edition

Harikumar Sukumar Pillay, a former director at the Competition and Consumer Commission of Singapore, joins OC Queen Street as a director as the competition watchdog recently expanded its regulatory powers.

By John Kang

3 minute read

August 30, 2018 | International Edition

Environment and planning lawyer Jacinta Studdert is the third partner so far this year to leave the global legal giant for Clyde & Co in Australia.

By John Kang

2 minute read

August 30, 2018 | International Edition

The name change decision comes a decade after Mayer Brown merged with leading Hong Kong firm Johnson Stokes & Master.

By John Kang

3 minute read

August 29, 2018 | International Edition

Cedric Lam joins as a corporate partner and head of intellectual property for Greater China.

By John Kang

2 minute read

August 28, 2018 | International Edition

Xiao Liu, who was recently promoted to counsel at Skadden, has relocated from Beijing to join the three-year-old office.

By John Kang

2 minute read

August 27, 2018 | International Edition

The share sale comes after the Chinese biopharmaceutical company rejected a $3.9 billion offer from a consortium led by its former CEO, David Gao, who said legal action may be taken against the company he once led from 2012 until June.

By John Kang

2 minute read